Clorox director reports new deferred stock unit awards and fees

Clorox Co. director reported routine equity-based compensation and fee deferrals in the form of deferred stock units.

Rhea-AI Filing Summary

Clorox Co. director reported routine equity-based compensation and fee deferrals in the form of deferred stock units. On 11/06/2025, the director acquired 8.9351 deferred stock units tied to Clorox common stock through dividend reinvestment under the Independent Directors' Deferred Compensation Plan, bringing the beneficially owned balance to 774.7598 units.

On 12/31/2025, the director received an annual award of 1,637.8577 deferred stock units under the 2005 Stock Incentive Plan, increasing holdings to 2,412.6175 units, and an additional 334.7218 deferred stock units in lieu of cash quarterly director fees, for a new total of 2,747.3393 units. All deferred stock units are scheduled to be settled 100% in Clorox stock after the director retires or otherwise leaves the board.

Insider Trade Summary

Grant/Award: 1,981.5146 shares

Grant/Award 3 txns

Insider Breber Pierre R

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Deferred Stock Units	1,637.8577	$0.00	$0.00
Grant/Award	Deferred Stock Units	334.7218	$0.00	$0.00
Grant/Award	Deferred Stock Units	8.9351	$0.00	$0.00

Holdings After Transaction: Deferred Stock Units — 2,747.3393 contracts (Direct)

Footnotes (5)

1. F1. 1-for-1
2. F2. Deferred Stock Units acquired through dividend reinvestment during the fiscal year pursuant to the Independent Directors' Deferred Compensation Plan.
3. F3. The Deferred Stock Units will be settled 100% in Clorox stock in connection with the reporting person's retirement or other termination of service as a Director.
4. F4. Annual award of Deferred Stock Units pursuant to the 2005 Stock Incentive Plan.
5. F5. Receipt of Deferred Stock Units in lieu of receipt of quarterly director's fees.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Clorox (CLX) report in this Form 4?

The filing reports that a Clorox Co. director acquired deferred stock units linked to Clorox common stock as part of director compensation and fee deferrals.

How many deferred stock units did the Clorox director receive on 11/06/2025?

On 11/06/2025, the director acquired 8.9351 deferred stock units through dividend reinvestment under the Independent Directors' Deferred Compensation Plan.

What equity awards did the Clorox (CLX) director receive on 12/31/2025?

On 12/31/2025, the director received an annual award of 1,637.8577 deferred stock units under the 2005 Stock Incentive Plan, plus 334.7218 deferred stock units in lieu of quarterly director fees.

What is the director’s total deferred stock unit holding after these transactions?

Following the reported transactions, the director beneficially owns 2,747.3393 deferred stock units tied to Clorox common stock.

How and when will the Clorox director’s deferred stock units be settled?

The deferred stock units will be settled 100% in Clorox stock when the director retires or otherwise terminates service from the board.

Why did the Clorox director receive some deferred stock units instead of cash fees?

A portion of the units, totaling 334.7218 deferred stock units, represents the receipt of deferred stock units in lieu of quarterly director fees.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/05/2026 - 04:43 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Breber Pierre R

(Last) (First) (Middle)

1221 BROADWAY

(Street)

OAKLAND CA 94612-1888

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CLOROX CO /DE/ [ CLX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/31/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Deferred Stock Units	(1)	11/06/2025		A(2)	V	8.9351		(3)	(3)	Common Stock	8.9351	$0.0000	774.7598	D
Deferred Stock Units	(1)	12/31/2025		A(4)		1,637.8577		(3)	(3)	Common Stock	1,637.8577	$0.0000	2,412.6175	D
Deferred Stock Units	(1)	12/31/2025		A(5)		334.7218		(3)	(3)	Common Stock	334.7218	$0.0000	2,747.3393	D

Explanation of Responses:

1. 1-for-1

2. Deferred Stock Units acquired through dividend reinvestment during the fiscal year pursuant to the Independent Directors' Deferred Compensation Plan.

3. The Deferred Stock Units will be settled 100% in Clorox stock in connection with the reporting person's retirement or other termination of service as a Director.

4. Annual award of Deferred Stock Units pursuant to the 2005 Stock Incentive Plan.

5. Receipt of Deferred Stock Units in lieu of receipt of quarterly director's fees.

	By Jinho Joo, Attorney-in-Fact	01/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.